In partnership with
Real-world data on brodalumab affirm efficacy and fast onset of action
Biologic psoriasis treatment and COVID-19 risk: still a matter of debate
Hidradenitis suppurativa: beware of psychiatric comorbidities and suicidal ideation
IL-23p19 class antibody efficacious in psoriasis management
Topical pan-JAK inhibitor achieved efficacy and fast onset in chronic hand eczema
JAK1 inhibition successful in hidradenitis suppurativa
Secukinumab: a new management option for paediatric severe psoriasis
Sleep quality of partners of psoriasis patients
Oral prevention of skin cancer
Low early PASI response could predict favourable outcomes for psoriasis patients on biologics
Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria
Impact of personal protective equipment on acne vulgaris and rosacea
New hope for epidermolysis bullosa patients
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
Efficacious non-steroidal topical for psoriasis
Zinc oxide coated socks against foot odour
Topical TYK2/JAK 1 inhibitor effective and tolerable in mild-to-moderate AD
Risky sexual behaviour and STIs on the rise despite the pandemic
Top image: @ iStockPhoto: ipopba
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP